BioWorld: Tolerogenic assets at heart of Cour-Genentech $940M autoimmune deal
COUR Pharmaceuticals Enters Collaboration and Licensing Agreement with Genentech to Develop and Commercialize Tolerogenic Therapy for the Treatment of an Autoimmune Disease
